Longeveron (NASDAQ:LGVN) Lowered to Sell Rating by Wall Street Zen

Longeveron (NASDAQ:LGVN) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently commented on LGVN. Maxim Group downgraded Longeveron from a “buy” rating to a “hold” rating in a report on Monday, May 11th. HC Wainwright reduced their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, May 4th. Finally, Weiss Ratings lowered Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Longeveron currently has a consensus rating of “Hold” and a consensus target price of $5.50.

Longeveron Price Performance

LGVN opened at $0.62 on Friday. The company has a fifty day moving average price of $0.74 and a two-hundred day moving average price of $0.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.88 and a current ratio of 3.88. Longeveron has a 52 week low of $0.47 and a 52 week high of $1.80. The firm has a market capitalization of $19.38 million, a PE ratio of -0.55 and a beta of -0.35.

Longeveron (NASDAQ:LGVN) last issued its earnings results on Wednesday, May 13th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.33 million. As a group, analysts anticipate that Longeveron will post -0.68 earnings per share for the current year.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron at the end of the most recent quarter. 10.01% of the stock is owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.